8-K: Cadrenal Therapeutics Gains FDA Alignment on Phase 3 HIT Study

Cadrenal Therapeutics announced positive feedback from an FDA Type D meeting, aligning on key aspects of the protocol and Statistical Analysis Plan for its Phase 3 registrational study of CAD-1005 for Heparin-Induced Thrombocytopenia (HIT).

Summary

• Cadrenal Therapeutics received positive feedback from the U.S. Food and Drug Administration (FDA) following a Type D meeting on July 28, 2026.
• The meeting focused on the Phase 3 registrational study protocol and Statistical Analysis Plan for CAD-1005, a 12-lipoxygenase (12-LOX) inhibitor intended to treat Heparin-Induced Thrombocytopenia (HIT).
• The FDA agreed on an optimized definition of worsening HIT for the primary endpoint, which will now include progression of thrombotic events through Day 14 of treatment or hospital discharge, and extension of existing thrombus into a new vascular segment or bed.
• The updated composite primary endpoint will measure the proportion of Serotonin Release Assay-positive (SRA+) participants with adjudicated new or worsening composite thromboembolic events (CTEs) through Day 14 or hospital discharge.
• The FDA also agreed to the use of a placebo control in the Phase 3 trial, with both the CAD-1005 and placebo arms receiving existing standard anticoagulation therapeutics.
• CAD-1005 targets a significant unmet need in HIT, a condition affecting approximately 50,000 patients annually in the U.S., with a projected peak annual revenue of $2 billion.
• The company also has other pipeline candidates, including tecarfarin for chronic anticoagulation and frunexian.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, indicating significant progress and alignment with regulatory bodies for a key drug candidate.

Positives

• Alignment with the FDA on key aspects of the Phase 3 study protocol and Statistical Analysis Plan for CAD-1005.
• Agreement on an optimized definition for the primary endpoint of worsening HIT, enhancing reliability and reducing variability.
• FDA agreement to use a placebo control in the Phase 3 trial, a standard for registrational studies.
• CAD-1005 targets a significant unmet medical need in HIT, with an estimated $2 billion peak annual revenue potential.
• CAD-1005 has Orphan Drug Designation (ODD) and Fast Track designation from the FDA for HIT.
• The company's CEO expressed satisfaction with the collaborative and constructive feedback from the FDA, providing clarity on the regulatory path forward.

Negatives

• The filing does not explicitly mention any negative outcomes or setbacks.
• The success of CAD-1005 is still contingent on the positive results of the upcoming Phase 3 trial.

Risks

• The forward-looking statements indicate that actual results may differ materially from expectations due to various factors, including the company's ability to advance its programs, secure development and commercialization transactions, and obtain grants.
• The company's ability to successfully complete the Phase 3 trial and obtain regulatory approval for CAD-1005 is subject to inherent risks in drug development.
• The filing references the company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings, which may contain further risk disclosures.

Future Outlook

The company has aligned with the FDA on the protocol and Statistical Analysis Plan for a Phase 3 registrational study of CAD-1005. The study will evaluate CAD-1005's efficacy in reducing thrombotic events in HIT patients and will assess bleeding as a major safety endpoint. The company anticipates this alignment provides clarity on the regulatory path forward.

Management Comments

• "We are very pleased with the collaborative, constructive feedback from the FDA during this Type D meeting," said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics.
• "Securing agreement on the primary endpoint definition and the blinding protocols for our saline control provides greater clarity on the regulatory path forward for CAD-1005."
• "We have incorporated the Agencys recommendations into our Phase 3 protocol and Statistical Analysis Plan, strengthening the design of a registration study intended to evaluate whether CAD-1005 can reduce dangerous thrombotic events that persist in patients with HIT despite current anticoagulant therapies."

Industry Context

StockSavvy.ai notes that this announcement is significant for the biopharmaceutical industry, particularly in the critical care cardiology and orphan cardiovascular conditions space. Achieving FDA alignment on a Phase 3 protocol for a novel therapeutic like CAD-1005 is a crucial step towards potential market entry for a drug addressing a serious unmet need like HIT. The projected $2 billion peak revenue potential highlights the commercial significance of this development.

Comparison to Industry Standards

• The FDA's agreement to a placebo-controlled Phase 3 trial using standard anticoagulation in both arms aligns with industry standards for establishing the efficacy and safety of new therapeutics.
• The refined composite primary endpoint, incorporating specific definitions of worsening HIT and thromboembolic events, aims to improve the robustness and reliability of trial results, a common goal in modern clinical trial design.
• The use of standard International Society on Thrombosis and Haemostasis (ISTH) criteria for assessing bleeding as a safety endpoint is a widely accepted industry practice.

Stakeholder Impact

• Shareholders: Positive development likely to be viewed favorably, potentially impacting stock price positively due to progress in drug development and regulatory clarity.
• Patients with HIT: Potential for a new, targeted therapeutic option that addresses the underlying mechanisms of the disease, beyond current anticoagulation therapies.
• Healthcare Providers: Clarity on the path forward for CAD-1005 may influence treatment strategies and clinical trial participation decisions.

Next Steps

• Incorporate FDA recommendations into the Phase 3 protocol and Statistical Analysis Plan.
• Proceed with the Phase 3 registrational study of CAD-1005.
• Evaluate whether CAD-1005 can reduce dangerous thrombotic events in patients with HIT.
• Assess bleeding as a major safety endpoint using standard ISTH criteria in the Phase 3 trial.

Key Dates

Recommendation

The filing represents a significant positive step in the regulatory process for CAD-1005, with clear FDA alignment on the Phase 3 study design. However, the drug is still in Phase 3 development, and its ultimate success and market potential are not yet confirmed. Therefore, a 'hold' recommendation is appropriate, pending further clinical trial results and regulatory outcomes.

Keywords

Heparin-Induced Thrombocytopenia, CAD-1005, FDA, Phase 3 Study, 12-LOX inhibitor, Thrombosis, Biopharmaceutical, Clinical Trial Protocol